Understanding the Role of Natural Amyloid Beta-Specific B Cell Responses in Alzheimer’s Disease Progression

2021

The U.S. Food and Drug Administration recently approved aducanumab, an antibody that promotes clearance of amyloid beta plaques in patients with Alzheimer’s disease. Here we propose to study whether Alzheimer’s disease is associated with the development of natural antibodies against amyloid beta plaques, whether these antibodies attenuate disease progression and whether their presence can help identify patients who will benefit from antibody therapy.


Funding to Date

$172,500

Focus

Studies of Innate Immune Pathology, Translational

Researchers

Marco Colonna, M.D.